OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
AONC.PK55

American Oncology Network Inc

Healthcare Facilities & ServicesVerified

American Oncology Network Inc has a debt-to-equity ratio of 1.36, indicating a moderate level of leverage, while its current ratio of 1.69 suggests it has sufficient short-term assets to cover its liabilities. The company's liquidity position is assessed as medium, with negative free cash flow of -$1.96 million and operating cash flow of -$329,000, signaling potential challenges in maintaining operational liquidity. Profitability metrics show a return on equity of -2.45% and a return on assets of -0.44%, both significantly below the industry median for healthcare facilities and services. The company reported a net loss of $1.49 million and an operating loss of $491,000, indicating a lack of profitability compared to industry peers. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts that could impact its operations. The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year. The absence of positive revenue growth, combined with negative operating and net income, suggests a challenging operating environment. Risk factors include a medium liquidity risk due to negative free cash flow and a debt load that exceeds equity. The company has a low dilution risk, with no near-term pressure for additional equity issuance. However, the negative net cash position after subtracting total debt raises concerns about its ability to meet long-term obligations. Recent filings and transcripts have not disclosed any material events that would significantly alter the company's financial or operational outlook. The company remains in a loss-making position, with no clear path to profitability in the near term.

30-day price · AONC.PK(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyAmerican Oncology Network Inc
TickerAONC.PK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. American Oncology Network Inc provides oncology services and operates cancer treatment centers, generating revenue primarily through patient care and insurance reimbursements.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

American Oncology Network Inc has a debt-to-equity ratio of 1.36, indicating a moderate level of leverage, while its current ratio of 1.69 suggests it has sufficient short-term assets to cover its liabilities. The company's liquidity position is assessed as medium, with negative free cash flow of -$1.96 million and operating cash flow of -$329,000, signaling potential challenges in maintaining operational liquidity. Profitability metrics show a return on equity of -2.45% and a return on assets of -0.44%, both significantly below the industry median for healthcare facilities and services. The company reported a net loss of $1.49 million and an operating loss of $491,000, indicating a lack of profitability compared to industry peers. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts that could impact its operations. The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year. The absence of positive revenue growth, combined with negative operating and net income, suggests a challenging operating environment. Risk factors include a medium liquidity risk due to negative free cash flow and a debt load that exceeds equity. The company has a low dilution risk, with no near-term pressure for additional equity issuance. However, the negative net cash position after subtracting total debt raises concerns about its ability to meet long-term obligations. Recent filings and transcripts have not disclosed any material events that would significantly alter the company's financial or operational outlook. The company remains in a loss-making position, with no clear path to profitability in the near term.
Key takeaways
  • American Oncology Network Inc is operating at a loss, with negative net income and operating income.
  • The company's liquidity is constrained, with negative free cash flow and a debt-to-equity ratio of 1.36.
  • Profitability metrics are well below industry medians, indicating poor performance relative to peers.
  • The company lacks geographic and segment diversification, increasing its exposure to regional and operational risks.
  • No significant growth in revenue has been reported, and the outlook for profitability remains uncertain.
  • # RATIONALES
  • {
  • "margin_outlook_rationale": "Margins are expected to remain under pressure due to the company's current operating losses and lack of gross profit growth.",
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$303.7M
Gross profit$25.2M
Operating income-$491.0k
Net income-$1.5M
R&D
SG&A
D&A
SBC
Operating cash flow-$329.0k
CapEx-$2.8M
Free cash flow-$2.0M
Total assets$336.2M
Total liabilities$275.6M
Total equity$60.6M
Cash & equivalents$23.8M
Long-term debt$82.4M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$724.7M$22.1M$0.00$13.4M
FY-3$943.7M$911.0k$0.00-$2.3M
FY-2$1.15B$5.6M$0.00$2.1M
FY-1$1.28B-$49.2M-$5.5M-$70.3M
FY0$1.76B-$17.4M-$4.0M-$43.1M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4
FY-3$248.3M$59.5M$27.4M
FY-2$326.2M$62.0M$26.9M
FY-1$374.5M-$96.7M$28.5M
FY0$470.3M$18.8M$62.8M
PeriodOCFCapExFCFSBC
FY-4$37.2M-$12.2M$13.4M
FY-3-$26.3M-$8.3M-$2.3M
FY-2-$6.8M-$7.2M$2.1M
FY-1-$18.1M-$12.3M-$70.3M
FY0-$4.9M-$21.0M-$43.1M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$303.7M-$491.0k-$1.5M-$2.0M
FQ-6$315.0M-$3.7M-$10.1M-$12.0M
FQ-5$336.3M-$24.4M-$1.8M-$32.0M
FQ-4$324.2M-$20.6M-$3.8M-$24.4M
FQ-3$364.3M-$19.2M-$7.8M-$28.0M
FQ-2$434.0M-$8.0M$3.6M-$6.0M
FQ-1$470.3M$1.6M-$1.1M-$6.9M
FQ0$490.9M$8.2M$1.3M-$2.2M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$336.2M$60.6M$23.8M
FQ-6$398.0M$107.5M$72.7M
FQ-5$394.0M-$276.3M$51.7M
FQ-4$374.5M-$96.7M$28.5M
FQ-3$421.9M-$102.5M$74.9M
FQ-2$430.8M$25.0M$33.8M
FQ-1$394.8M-$38.8M$19.4M
FQ0$470.3M$18.8M$62.8M
PeriodOCFCapExFCFSBC
FQ-7-$329.0k-$2.8M-$2.0M
FQ-6-$2.3M-$6.9M-$12.0M
FQ-5-$6.2M-$9.5M-$32.0M
FQ-4-$18.1M-$12.3M-$24.4M
FQ-3$45.1M-$4.1M-$28.0M
FQ-2$11.2M-$8.2M-$6.0M
FQ-1-$16.9M-$14.6M-$6.9M
FQ0-$4.9M-$21.0M-$2.2M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$60.6M
Net cash-$58.6M
Current ratio1.7
Debt/Equity1.4
ROA-0.4%
ROE-2.5%
Cash conversion22.0%
CapEx/Revenue-0.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
MetricAONC.PKActivity
Op margin-0.2%5.6% medp25 -4.2% · p75 12.6%below median
Net margin-0.5%2.8% medp25 -3.4% · p75 8.8%below median
Gross margin8.3%36.5% medp25 23.7% · p75 65.2%bottom quartile
CapEx / revenue-0.9%-4.9% medp25 -11.5% · p75 -2.0%top quartile
Debt / equity136.0%69.3% medp25 7.9% · p75 120.9%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 05:40 UTC#5cd664cd
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 09:05 UTCJob: 720465d9